Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Centessa Pharmaceuticals PLC - ADR before investing.

In this article, we go over a few key elements for understanding Centessa Pharmaceuticals PLC - ADR’s stock price such as:

• Centessa Pharmaceuticals PLC - ADR’s current stock price and volume
• Why Centessa Pharmaceuticals PLC - ADR’s stock price changed recently
• Upgrades and downgrades for CNTA from analysts
• CNTA’s stock price momentum as measured by its relative strength

About Centessa Pharmaceuticals PLC - ADR (CNTA)

Before we jump into Centessa Pharmaceuticals PLC - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

Want to learn more about Centessa Pharmaceuticals PLC - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Centessa Pharmaceuticals PLC - ADR.

Centessa Pharmaceuticals PLC - ADR’s Stock Price as of Market Close

As of April 03, 2024, 4:00 PM, CST, Centessa Pharmaceuticals PLC - ADR’s stock price was $10.82.

Centessa Pharmaceuticals PLC - ADR is down 4.5% from its previous closing price of $11.33.

During the last market session, Centessa Pharmaceuticals PLC - ADR’s stock traded between $10.57 and $11.37. Currently, there are 97.94 million shares of Centessa Pharmaceuticals PLC - ADR stock available for purchase.

Unfortunately, Centessa Pharmaceuticals PLC - ADR’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Centessa Pharmaceuticals PLC - ADR Stock Price History

Centessa Pharmaceuticals PLC - ADR’s (CNTA) price is currently down 4.25% so far this month.

During the month of April, Centessa Pharmaceuticals PLC - ADR’s stock price has reached a high of $11.48 and a low of $10.56.

Over the last year, Centessa Pharmaceuticals PLC - ADR has hit prices as high as $12.45 and as low as $3.52. Year to date, Centessa Pharmaceuticals PLC - ADR’s stock is up 249.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Centessa Pharmaceuticals PLC - ADR Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 02, 2024, there were 0 analysts who downgraded Centessa Pharmaceuticals PLC - ADR’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Centessa Pharmaceuticals PLC - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Centessa Pharmaceuticals PLC - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Centessa Pharmaceuticals PLC - ADR’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Centessa Pharmaceuticals PLC - ADR (CNTA) by visiting AAII Stock Evaluator.

Relative Price Strength of Centessa Pharmaceuticals PLC - ADR

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 02, 2024, Centessa Pharmaceuticals PLC - ADR has a weighted four-quarter relative price strength of 25.49%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Centessa Pharmaceuticals PLC - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Centessa Pharmaceuticals PLC - ADR Stock Price: Bottom Line

As of April 3, 2024, Centessa Pharmaceuticals PLC - ADR’s stock price is $10.82, which is down 4.5% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Centessa Pharmaceuticals PLC - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.